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a b s t r a c t
Mutations in the thumb subdomain of reverse transcriptase (RT) of HIV-1 can cause this enzyme to be
degraded in virions by the viral protease (PR). Many of these mutations confer a temperature-sensitive
phenotype on RT and viral replication. The degradation of RT by PR appears to take place after Gag-Pol
has been processed. We show here that mutations in other parts of RT, including the RNase H domain,
can make RT PR-sensitive and temperature-sensitive. These data explain why some mutations in the
RNase H domain, which had little or no effect on the polymerase activity of puriﬁed recombinant RT, had
a profound effect on viral titer. Because the PR-sensitive phenotype signiﬁcantly reduced viral titer, we
previously suggested that these mutations would be selected against in patients. We also show that RT
mutations that are known to confer a temperature sensitive phenotype are rarely found in the Stanford
database.
Published by Elsevier Inc.
Introduction
The reverse transcriptase (RT), protease (PR), and integrase (IN)
of HIV-1 are the three essential virally encoded enzymes that are
the primary targets for anti-HIV drug therapy. RT carries out the
conversion of the single-stranded RNA genome found in virions
into a double-stranded DNA form that is inserted into the host
genome by IN. This conversion requires both of the enzymatic
activities of RT; a DNA polymerase that can copy either an RNA or a
DNA template, and an RNase H that cleaves RNA if (and only if) it is
part of an RNA:DNA duplex. Although there are two broad classes
of drugs that block the reverse transcription of the viral RNA
genome, both block the polymerase step. One class includes the
nucleoside analogs, or NRTIs, all of which lack a 3' OH and, when
incorporated by RT, block the synthesis of viral DNA. The second
class, nonnucleoside RT inhibitors (NNRTIs), bind in a hydrophobic
pocket of RT, about 10 Å from the polymerase active site. This
binding distorts RT in a way that pushes the end of the viral DNA
away from the polymerase active site, preventing polymerization
(Das et al., 2012).
Unfortunately, HIV-1 has been able to develop resistance to all
of the available drugs, including all of the NRTIs and NNRTIs. Thus
it is important to understand the limitations of the variability of
HIV-1 RT, because it is the variability of the viral components that
are drug targets that underlies the ability of the virus to develop
drug resistance. In this sense, it is important to understand not
only the mutations that arise in RT in response to drug selection,
but also to try to better understand why other changes in RT are
not commonly seen.
As part of an analysis of the RNase H domain of HIV-1 reverse
transcriptase (RT), we made alanine substitution mutations to
some of the residues in RNase H that helps to properly position the
nucleic acid heteroduplex for cleavage: the RNase H primer grip
(Julias et al., 2002). Three single mutations, T473A, Q475A, Y501A,
and a double mutation, N474A/Q475A, all had a substantial impact
on the ability of a viral vector to replicate in a one round assay. The
T473A mutation blocked viral replication and the Q475A, Y501A,
and N474A/Q475A mutations reduced the titer 5–10 fold (Julias
et al., 2002). The ability of viral vectors carrying either the Y501A
mutation, or the N474A/Q475A double mutation, to synthesize
viral DNA was measured in infected cells; both of these mutant
vectors made much less viral DNA than the corresponding WT
vector. Moreover, for both of these mutants, the magnitude of the
defects seen in the synthesis of RU5, U3, gag, and plus-strand
transfer DNA (late stage viral DNA) were similar, suggesting that a
problem occurred early in viral DNA synthesis, perhaps during the
initiation of minus-strand DNA. However, analysis done in paral-
lel with puriﬁed recombinant RTs showed that all four of these
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mutant RTs were able to synthesize DNA at levels, comparable to
WT RT, using a DNA primer and a DNA template, and that they
were also approximately equivalent to WT in a polymerization
assay using an RNA template and a tRNA lys3 primer that was
designed to mimic the initiation of minus strand DNA synthesis
(Rausch et al., 2002). Although it was possible, as we suggested,
that the conditions in the virion core made it particularly difﬁcult
for these RT mutants to initiate viral DNA synthesis in an infected
cell, the behavior of the puriﬁed mutant RTs did not match, or
explain, the defect in the ability of viruses carrying these same
mutations to replicate. Why did these mutant RTs appear to
behave differently in vitro and in infected cells?
During the maturation of the virus, the viral protease (PR)
cleaves a variety of sequences within the Gag and Gag-Pol
polyproteins. However, not all of the sequences in these poly-
proteins are treated equally by PR. To cite an obvious example, in
the maturation of HIV-1 RT, there is only limited processing of a
site in HIV-1 RT near the boundary between the polymerase and
RNase H domains. HIV-1 RT is a heterodimeric enzyme. The two
subunits, p66 and p51, share a common N-terminus; however, the
larger subunit is 560 amino acids long, and the smaller subunit is
440 amino acids long. Thus, only half of the RT precursors are
cleaved by PR to produce p51. The cleavage site used to produce
the p51 subunit, which is present in the p66 subunit, is not cleaved
in p66, suggesting that the structure (folding) of the RT subunits
can affect whether a site is cleaved or not. This idea is supported
by a scan of the sequences in the p66 subunit, which suggests that
there are additional sites in RT that could be cleaved if PR had
access to them, and by experiments which showed that RT could
be degraded by PR at low pH (Chou et al., 1996; Tomasselli et al.,
1993). These data support the idea that PR might degrade an
unfolded, or partially unfolded, RT much more extensively than
the properly folded heterodimeric enzyme.
Both we and others have shown that there are mutations in
HIV-1 RT that allow it to be extensively degraded in virions by the
viral PR (Dunn et al., 2013, 2009; Huang et al., 2003, 1998;
Takehisa et al., 2007; Wapling et al., 2005; Wang et al., 2010).
Although the degree to which RT is degraded can vary, depending
on which mutation is present, the mutations that have a profound
effect on the amount of intact RT in virions also have a profound
negative impact on the ability of the virus to replicate. Most of the
protease-sensitive mutations that we previously described are in
the thumb subdomain (Dunn et al., 2013, 2009). Many of these
protease-sensitive mutations also caused viral replication (and the
underlying degradation of RT) to be temperature sensitive (TS). In
a one-round assay, the mutant viruses replicated much better at
32 oC than at 37 oC. In virions carrying the TS RT mutants that
were grown at 37 oC, there was, judged by a western blot, less
intact RT than in WT virions, suggesting that the higher tempera-
ture allowed RT to partially unfold, exposing sites that could be
cleaved by PR. In some cases, when the virions that carried the
mutant RTs were grown at 37 oC, they contained proteolytic
fragments of RT. Although RT was degraded (or partially degraded)
in the mutant virions, the amounts of full-length PR and IN were
normal, or nearly normal. Thus, the degradation of RT by PR
appeared to take place after the initial processing of Gag-Pol.
We puriﬁed recombinant forms of some of the mutant RTs and
showed that the mutant RTs were partially unfolded at the non-
permissive temperature (Dunn et al., 2013). Parallel analysis of the
mutant RTs in virions showed that the mutant RTs were degraded
by the viral PR. The polymerase domains of both the p51 and p66
subunits are encoded by the same segment of the viral genome.
Thus, any mutation that arises in the polymerase domain will be
present twice in the mature heterodimeric enzyme, once in the
large subunit (p66) and in once the small subunit (p51). We
prepared recombinant forms of RT that had TS mutations present
in only one of the two subunits, and showed that having the amino
acid change in either p66 or p51 contributed to the propensity of
RT to partially unfold at a the higher (non-permissive) tempera-
ture (Dunn et al., 2013).
In the experiments described here, we were particularly inter-
ested in the three RNase H primer grip mutants, not only because
these mutants had a change in only one of two subunits of RT
(p66), but also because these mutants represented particularly
well-characterized examples in which data obtained with puriﬁed
recombinant RTs and viral vectors carrying the same mutations
did not appear to agree (Julias et al., 2002; Rausch et al., 2002). We
show here that the RNase H mutants have a TS phenotype and that
these mutant RTs are degraded in virions at 37 oC. That is similar to
the PR-sensitive thumb mutants we previously described. Because
most of the mutants we previously analyzed were in the thumb
subdomain, we also analyzed some additional mutants that have
changes in the ﬁngers and palm subdomains, and showed that
they also have a TS phenotype, and that this phenotype is linked to
the degradation of RT in virions. We tested the effects of these
additional RT mutations, both in the RNase H domain and in the
polymerase domain, on the processing of a Pol polyprotein
expressed in E. coli, and used this system to show that these
mutations in RT directly affect its susceptibility to the viral PR,
outside of the context of the virion. This shows that mutations that
cause HIV-1 RT to become PR-sensitive can occur in the RNase H
domain, and in several of the subdomains of the polymerase
domain. These data conﬁrm and extend our previous observations,
showing that mutations in any part of HIV-1 RT can affect the
susceptibility of RT to PR.
Because mutations that make RT PR-sensitive can have a
profound effect on viral replication, we previously proposed that
these mutations can constrain the spectrum of amino acid changes
that HIV-1 can tolerate in RT (Dunn et al., 2009). In support of this
idea, we analyzed the frequencies at which the mutations that
make RT susceptible to PR appear in viruses in patients, using the
Stanford database. As we predicted, the PR-sensitive mutations in
RT make up only a small fraction of the amino acids found at their
respective positions in RT.
Results and discussion
Mutations in the ﬁngers and palm subdomains and in the RNase H
domain of HIV-1 RT can lead to the proteolytic degradation of RT in
virions
We began by investigating the effects of three mutations in a
portion of RNase H called the primer grip: T473A, Q475A, and
Y501A, on the stability of RT in virions. The positions, in HIV-1 RT,
of the amino acids where mutations caused RT to become sensitive
to PR are shown in Fig. 1. Virions were prepared from cells grown
at 37 oC; the amount of intact RT was monitored by doing western
blots. We also tested one double mutant in the primer grip, N474A/
Q475A. As described in the Introduction, all of these mutations
had been shown to interfere with the ability of the virus to initiate
viral DNA synthesis, but none of the mutations had much effect on
the polymerase activity of the corresponding puriﬁed recombinant
RTs (Julias et al., 2002; Rausch et al., 2002). All four of these RNase
H mutants showed signs, in a western blot, of RT degradation in
virions (diminished levels of RT, and/or the presence of proteolytic
fragments of RT, see Fig. 2). A western blot, performed for the
virion protein capsid (CA), showed that the approximately same
amount of virions were present in the lysates that were used in the
western blots of RT, and that Gag was appropriately processed by
PR. There was some variation in the amount of p55 Gag, and a Gag
processing intermediate, in some of the samples. However, there
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was also some variation in the amount of p55, and the processing
intermediate, in the various WT controls used in the blots (Fig. 2).
We also analyzed the effects of two mutations in the ﬁngers,
G45L and I63S, both of which appeared to have, in virions, lower
amounts of at least one of the RT subunits than WT (Fig. 2). In
contrast, the drug resistance mutation L74V, which is also in the
ﬁngers, did not appear to cause any increased degradation of RT
(data not shown). Of the mutations we analyzed in the palm
subdomain, three, V111S, N136Q, and I159S, appeared to lead to a
partial degradation of RT in virions (Fig. 2); however, virions
containing RTs carrying the palm subdomain mutants Q91A,
L92A, G93A, and P157A, appeared to have normal, or nearly
normal amounts of undegraded RT (data not shown). We also
analyzed one additional mutation in the palm (G190E) that is
known to affect the susceptibility of the virus to nonnucleoside RT
inhibitors (NNRTIs); RTs carrying this mutation were previously
shown to be degraded in virions (Huang et al., 2003).
Based on the results of the analysis of the mutations in the
thumb of HIV-1 RT, we expected that many of the protease-
sensitive RT mutants would be TS. All of the mutants that showed
signs of RT degradation were tested for their ability to infect cells
with viruses grown at either 37 oC or at 32 oC (Table 1). With the
possible exception of the G45L mutant, for which the difference in
the infectivity of the viruses at the two temperatures is relatively
small, all of the viral mutants which showed signs of RT degrada-
tion were TS for replication. Because the Q475A mutant was TS, we
did not test the N474A/Q475A double mutant. The effects of
reducing the temperature on the ability of the virus to replicate
were, in some cases, quite dramatic, particularly for the mutants
that showed the greatest amounts of RT degradation when the
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Fig. 1. The positions, in HIV-1 RT, of the amino acids where mutations caused RT to
become sensitive to PR. The ﬁgure shows a ribbon diagram of the mature HIV-1 RT
heterodimer. The larger subunit, p66, is shown in orange, the smaller subunit, p51,
is shown in purple. The side chains of the amino acids of interest are shown. The
labels of the amino acids are color coded: Red is surface exposed, blue is buried,
and green is semi-buried. With the exception of the three amino acids in the RNase
H domain (T473, Q475, and Y501), the amino acids are present in both subunits.
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Fig. 2. The HIV-1 RT mutants are more extensively degraded in virions at 37 oC
than at 32 oC. Virions were harvested from cells grown at either 32 oC or 37 oC (see
Methods). The virions were collected by sedimentation, lysed, and the proteins
fractioned using SDS-PAGE. The proteins were transferred to nitrocellulose, and the
blots were probed with antibodies that react with HIV-1 proteins. Panel A. Western
blots from virions grown at 37 oC. In the portion of the experiment shown at the
top, the blots were probed with a mixture of monoclonal antibodies that react with
HIV-1 RT. The positions of migration of molecular weight markers are indicated on
the left; the positions where the p66 and p51 subunits migrate are indicated on the
right. The panel shows data from four different blots; there is a separate WT control
for the data from each of the four blots. In the center of the panel is a western blot
done with anti-CA antisera; this serves as a loading control and shows that PR was
able to properly process Gag. At the bottom of the panel is a blot done with anti-IN
antisera. To do the analysis of the processing of IN and CA, the RT blots were
stripped and reprobed with the appropriate antibodies. Panel B. The western blots
correspond to the western blots shown in Panel A, except that the virions were
grown at 32 oC. As in Panel A, there were four separate blots done. For all of the
mutants, and all of the blots, the 37 oC and 32 oC samples were processed together.
The western blots were repeated three times, and representative data are shown.
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virions were grown at 37 oC (for example I63S, G190E, and T473A).
As would be expected, based on the increase in viral titer at the
permissive temperature, there was also an increase in the amount
of undegraded RT in the virions when the mutant virions were
grown at 32 oC. Conversely, G45L and V111S had much more
modest effects on both stability and titer. There were two muta-
tions (V118S and N136Q), both of which had a strong effect on the
titer at the non-permissive temperature, that appeared to have a
more modest effect on the amount of intact p66 and p51 in virions.
However, it should be remembered that multiple RTs must
cooperate to complete viral DNA synthesis and that reducing the
amount of polymerase activity in virions by more than about half
had a profound impact on viral titer (Julias et al., 2001). When the
mutant viruses were grown at 32 oC, only the RT that carried the
T473A mutation still showed clear signs of proteolytic degradation,
but there was, for this mutant RT, a substantial increase in the
amount of both intact p66 and intact p51 that was present in
virions (Fig. 2).
We previously showed, for a number of other RT mutants that
had a TS phenotype, that the proteolytic processing of Gag-Pol was
reasonably normal, in terms of the maturation of both PR and IN
(Dunn et al., 2009). Because the RNase H mutations were much
nearer IN than any of the mutations we previously analyzed, we
checked the effects of the three single RNase H mutations (T473A,
Q475A, and Y501A) and the double mutation (N474A/Q475A) to
see if the virions containing these RT mutations also contained the
normal amount of processed IN. As judged by western blot, when
virions containing each of these mutations in RT were grown at
either 37 oC or at 32 oC, the virions contained normal, or nearly
normal, amounts of processed IN (Fig. 2).
The HIV-1 RT mutants that are PR-sensitive in virions are also
PR-sensitive when expressed in E. coli.
We previously described an E. coli system, based on the
expressing of the Pol portion of the HIV-1 Gag-Pol polyprotein
(Dunn et al., 2013) that can be used to monitor the expression and
proteolytic processing of the RT, PR, and IN proteins; the system
we use is similar to one developed earlier by Wrobel et al. (1998).
The synthesis of the Pol polyprotein can be induced in bacteria
that are being grown at either 30 oC or at 37 oC. This makes it
Table 1
Mutant RTs lead to a temperature sensitive phenotype for viral replication. The
table lists the mutants, their location within RT, and the relative titer at the
permissive and non-permissive temperatures. The relative titers of the mutants are
expressed as the percentage of the relative titer of the WT.
Mutant Location (p66/p51) Relative Titer 371
(SD)
Relative titer
321(SD)
G45L Fingers (surface exposed; surface
exposed)
61.6 (23.5) 80.0 (14.7)
I63S Fingers (surface exposed; buried) 1.5 (0.8) 88.0 (11.8)
V111S Palm (semi-buried; semi-buried) 30.6 (10.6) 65.0 (24.6)
V118S Palm (buried; surface exposed) 1.3 (0.5) 55.3 (4.5)
N136Q Fingers (surface exposed;buried) 1.5 (1.1) 89.0 (15.6)
I159S Palm (buried;semi-buried) 2.0 (1.6) 70.6 (21.1)
G190E Palm (buried;buried) 2.7 (1.4) 84.0 (16.1)
T473A RNase H (surface exposed) 2.5 (1.5) 80.0 (2.4)
Q475A RNase H (surface exposed) 9.6 (2.6) 71.3 (19.5)
Y501A RNase H (surface exposed) 12.2 (4.5) 98.0 (2.8)
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Fig. 3. The mutant RTs are degraded when Pol is expressed in E. coli at 37 oC; IN
and PR are appropriately cleaved form Pol. Pol polyproteins that contained
either WT or mutant RTs were expressed in E. coli. The bacteria were grown at
either 37 oC (top), or 30 oC (bottom) and collected by centrifugation. The
bacteria were lysed and the lysates separated into insoluble and soluble
fractions. Aliquots were denatured in SDS, fractionated on SDS-PAGE, trans-
ferred to nitrocellulose, and Western blotted with antibodies that could detect
RT (Panel A), IN (Panel B) and PR (Panel C). In the IN blot, the upper band
corresponds to full length IN and the lower band corresponds to an E. coli
protein detected by the rabbit polyclonal IN antiserum. The blots for RT (Panel
A) and IN (Panel B) gave dramatically stronger signals so the exposure shown in
the ﬁgure for panel A was made using an additional ﬁlm to reduce the signal.
The exposure was 20 s. One additional ﬁlm was used to reduce the signal for
Panel B and the exposure was for 2 min. The exposure for panel C had no
additional blocking ﬁlm and was for 66 min. The blots were initially reacted
with the anti-PR antibody then were stripped and re-probed with the anti-IN
antibody. The blots were stripped a second time and re-probed with the anti-RT
antibodies. The Western blot data shown in Fig. 2 for the three antibodies (to IN,
PR, and RT) were done with a single batch of E. coli extracts. The experiments
were repeated four times, with different extracts, and representative data are
shown in the ﬁgure.
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possible to compare the processing of Pol and the stability of RT in
the presence of PR at these two temperatures. We used 32 oC and
not 30 oC for the experiments in which we measured the amount
of intact RT in virions only because we were not able to grow the
human cells at 30 oC. After the Pol proteins have been expressed
for two hours, the bacteria are collected, washed, and lysed as
described previously (Dunn et al., 2013) with the exception that
50 mM DTT was added to all lysis solutions. The lysate was
separated into a soluble and an insoluble fraction by sedimenta-
tion. Both the soluble and the insoluble fractions were treated
with SDS and the proteins separated by SDS-PAGE; the Pol
proteins (PR, IN, and RT) were detected by western blot. Using
this system, we previously showed that the WT Pol polyprotein is
appropriately expressed and processed by PR at both temperatures
(Dunn et al., 2013); that result was reproduced in the experiments
we report here. We also showed, in this E. coli expression system,
that PR is responsible for degrading the protease-sensitive RT at
the non-permissive temperature. The mature forms of WT RT, PR,
and IN can be seen in the soluble fraction of the E. coli lysates at
both 30o and 37o (Fig. 3). As is the case in virions, PR carries out
the initial processing of the Pol proteins that contain the protease-
sensitive mutations in RT at both the permissive and nonpermis-
sive temperatures, judged by the presence, in the soluble portion
of the bacterial extracts, of the mature forms of IN and PR. About
half of the mature IN is insoluble when Pol is expressed and
processed in E. coli; this matches what we reported previously. A
portion of the processed PR is insoluble, and in the bacteria, some
of the insoluble PR became crosslinked-giving rise to the dimers,
trimers, tetramers, and some larger forms that were seen in the
gels; this was also seen previously in the experiments done with
WT RT and other RT mutants.
With some exceptions, which are discussed below, there is good
agreement between the impact of the mutations on the stability of
RT in virions, and in the E. coli expression system. With the possible
exception of I63S, all of the RTs that were protease sensitive in virions
also showed clear signs of instability at 37 oC in the E. coli expression
system. For example, one of the mutations that had the greatest
impact on RT stability in virions (I159S) also had the greatest impact
on RT stability in the E. coli expression system. Several of the other
mutations that had a profound effect on the titer at 37 oC also had an
obvious effect on the stability of RT in the E. coli system (V111S,
V118S, and T473A) When we looked at the impact of the mutations
in the RNase H domain, which are present only in the p66 subunit,
we found that the Y473A mutation primarily destabilized the p66
subunit in the E. coli Pol expression system. However, the Y473A
mutant did not have an obvious selective effect on the stability of the
p66 subunit in virions. Moreover, there were other mutations in RT
(V111S and V118S) that also seemed to have greater impact on the
stability of p66, relative to p51, in the E. coli expression system; these
same mutations did not appear to selectively sensitize the p66
subunit to degradation by PR in virions. The most obvious disconnect
between the E. coli stability data and the virion data involved G45L
and I63S. Looking at the residual titer at 37 oC (Table 1), it would
appear that the I63S mutation had the greater impact on RT,
although a western blot of lysates of virions carrying either of these
mutants grown at 37 oC showed evidence of intact p66 and p51.
However, in the E. coli system, the G45L mutant was much less stable
at 37 oC than was I63S. Because these samples were run side by side
in the virion experiments and the E. coli expression experiments, we
checked the sequences of all of the underlying plasmids, and
repeated all the experiments. The results matched the data shown
in Figs. 2 and 3 and in Table 1. There are several possible explanations
for these discrepancies. First, we are comparing the processing of
Gag-Pol and Pol, and the interior of the virion and E. coli are quite
different. In addition, the experiments were done with two sligh-
tly different versions of RT. In the virions, the RT was derived from
NL4–3; the E. coli Pol was derived from BH10. However, the only
difference in these RTs is that, in BH10, position 529 is a V, and in
NL4–3 it is an I. Thus, with some speciﬁc exceptions, there is
reasonably good agreement between the impact of the mutations
on the stability of RT in virions, and in an E. coli expression system
that produces PR and RT as part of a Pol polyprotein. This strengthens
and conﬁrms our previous conclusion that the primary factor that
determines how sensitive the various mutant RTs are to degradation
by PR is the degree to which the individual RTs are unfolded at 37 oC.
PR-sensitive mutations are found both on the surface of RT, and
buried in the protein.
In our previous analysis of PR-sensitive mutations in the thumb
subdomain, most of the mutations that caused RT to become PR
(and temperature) sensitive were in residues that were buried in
the thumb (Dunn et al., 2009). In many cases, the PR-sensitive
mutations in the thumb involved the substitution of a hydrophilic
side chain for a hydrophobic side chain. The PR-sensitive pheno-
type is a consequence of the mutant RT unfolding at a lower
temperature than WT RT, which makes it susceptible to degrada-
tion by PR. It is not surprising, therefore, that introducing a
hydrophilic residue into a buried hydrophobic region of both of
the subunits of RT tended to make it less stable, and more readily
degraded by PR (for example I257T, L264S, I274T, L279S, L310S).
There were mutations (L289A, A299L) in which substituting one
hydrophobic residue for another gave a similar phenotype. We
also showed that there were hydrophilic residues that could be
mutated to cause protease sensitivity (R78K, N265D, D256N,
E302Q). With the exception of R78K, these changes involved the
substitution of an amino acid with an acidic side chain with one
that has a basic side chain, or vice-versa. Some of the mutations
that led to protease sensitivity also either increased the size of the
side chain (G152A, G285A), or could have affected the preferred
orientation of the amino acid backbone (P150G), all of which could
interfere with the proper folding of RT.
Several of the additional mutants we describe here, which are
in the RNase H domain or subdomains of the polymerase domain
of RT other than the thumb, fall into these same groups as were
seen with the thumb mutants: for example, hydrophobic to
hydrophilic (I63S, V111S, I159S). Although the G190E mutation
causes a substantial increase in the size of the side chain, it is
likely, based on the properties of other G190 mutants (for
example, G190A and G190S) (Huang et al., 2003) that it is the
introduction of a charged residue into an interior portion of RT
that is largely hydrophobic, not the size of the side chain of the
new amino acid, that causes the G190E mutant to be PR sensitive.
However, the T473A, T475A and Y501A mutations are surface
residues, which are present only in the p66 subunit. In the WT
enzyme, these residues interact with the primer strand, and help
to position an RNA/DNA duplex for proper processing of the RNA
strand by RNase H. The fact that substitutions of these residues can
make RT PR-sensitive broadens the types of mutations that can
confer this phenotype. Not only do mutations located at positions
either buried in one or both of the subunits of the protein,
mutations in residues that reside on the surface can also confer
PR-sensitivity. Moreover, a variety of different types of amino acid
substitutions can confer this phenotype.
There are extensive opportunities for mutations to arise in RT in
patients
Errors are made during the replication of HIV-1 in cultured
cells at a frequency of approximately 105; this number is based
on experiments that were done in cells that do not appear to
express signiﬁcant amounts of the APOBEC proteins that are
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known to cause additional mutations in the HIV genome (Abram
et al., 2010; Mansky and Temin 1995; Mansky et al., 2003). Setting
aside the possibility that the host APOBEC proteins could increase
the overall error rate, this means, when the virus replicates, that
there is approximately one mutation in every 10 newly synthe-
sized viral genomes. Based on an analysis of mutations that arise
in one round of replication in a reporter gene carried by an HIV
vector, all mutations are not equally likely to occur. For example,
the majority of the mutations are base substitutions, and transi-
tions occur more frequently than transversions. Errors occur much
more frequently at some positions than at others. However, it has
been estimated that, in untreated patients, approximately 109 new
cells are infected every day (Ho et al., 1995; Wei et al., 1995).
Assuming that the overall mutation rate for HIV is similar in
patients and in cells in culture, this suggests that, in patients,
approximately 1010 new viral mutants are generated every
3 months. Thus the virus has, in patients, the opportunity to
broadly sample the genetic space that is available to it in a
relatively short time. This accounts for the fact that, even though
the majority of people are infected by a single virus, within a few
years, the single virus that initiates the infection evolves into a
swarm, and when the RNA genomes in the blood of patients in
whom the virus has been allowed to replicate for several years are
sequenced, the sequences are all different.
However, despite the fact that the sequences of these viral
genomes are all different, only a small subset of the changes that
could have occurred (and probably did occur) in the viral genome
are frequently seen in patients. The changes that are seen in
patients are, in general, those that have a relatively modest impact
on the ability of the virus to replicate. In some cases, speciﬁc
sequence changes are selected for, either because there is selective
pressure on the sequence of one (or more) of the viral proteins
from the host's immune system and/or from drug therapy. Gen-
erally speaking, mutations that are not seen frequently have a
signiﬁcant deleterious effect on viral replication. For example,
deletions and insertions in regions encoding the viral proteins,
particularly deletions and insertions that cause frameshifts, are
relatively rare. In thinking about the viral sequences that are well-
conserved, there are portions of the viral proteins that are
essential for their proper function; to cite a trivial example, the
catalytically critical residues of the active sites of the three viral
enzymes, RT, IN, and PR are all quite well conserved. In addition,
there are conserved regions of the viral genome that do not
encode proteins but that have functions that are essential for viral
replication.
The protease-sensitive mutations we identiﬁed in RT are rarely seen in
patient samples
Although a substantial fraction of the mutations in RT that are
rarely seen in patients have a strong negative impact on one or
both of the enzymatic activities of RT, it now appears that
mutations in RT that make it protease-sensitive in virions can also
limit the mutational changes that are available to the virus. We
looked at the protease-sensitive mutations in RT we report here,
and determined both the fraction of the sequences in the Stanford
database that have any amino acid change at the position of
interest, and also the fraction of the mutations at each of the
positions of interest in which the mutation matched the speciﬁc
protease-sensitive substitutions we studied. It is of course possible
that some of the other amino acid substitutions that could have
arisen at the position of interest could also be protease-sensitive.
The fraction of the total sequences that are mutant is low for most
of the positions (45, 63, 111, 118, 136, 159, 473, 475 and 501). Only
at positon 190, a position where NNRTI therapy selects for
mutations, is the ratio of sequences that are mutant to those that
are WT above 1–100 (0.067). Moreover, in most cases, not only is
the overall fraction that is mutant low, but, in addition, the
percentage of the sequences that carry any mutation at the
position of interest that is the identiﬁed protease sensitive muta-
tion is also quite low. This percentage can be zero (these mutations
that we identiﬁed as protease-sensitive were never seen in
patients: V111S, V118S, I159S, Q475A, and Y501A); it can be less
than 1% of the mutations at the position of interest: G45L, I63S,
N136Q, and T473A and it is 2.4% for G190E. There is only one case
(T473A) in which a large fraction of the substitutions at the
designated position are the identiﬁed protease-sensitive mutation
(40%). As has already been noted, having any amino acid substitu-
tion at position 473 is quite rare; overall the percentage of viruses
in the Stanford database that carry this speciﬁc protease-sensitive
mutation is approximately 0.1%.
It is possible that the fact that some of the protease-sensitive
mutations would take two nucleotide changes could have some
effect on the frequency at which they arise. However, as has
already been discussed, when HIV replicates in patients, it has an
opportunity to sample the available mutational space in a rela-
tively short time. This idea is supported by the fact that there are
well-known drug resistance mutations that require two nucleotide
changes. For example T215Y, which is a primary mutation for AZT
resistance, arises frequently when patients were given AZT mono-
therapy. In considering that result, it is important to remember
that, even if the drug is given alone, it still reduces the overall
replication of the virus, which will reduce the viral load, and the
virus's ability to sample amino acid substitutions in RT. Thus, it is
likely that the virus has a better opportunity to test the amino acid
substitutions in RT that require two nucleotide changes in the
absence of drug therapy than in the presence of drug therapy.
Because the T215Y mutation is readily selected by AZT mono-
therapy, it is likely that other amino acid changes that require two
nucleotide changes arise in the absence of drug therapy.
The results obtained with the G190E mutation are instructive
for two reasons. First, because it is a mutation that can confer
resistance to NNRTIs, it is a mutation that would be selected
during treatment with this class of drugs. However, the impact of
this mutation on the stability of HIV-1 RT appears to limit the
frequency with which it is selected in patients. There are other
amino acid substitutions at position 190 that are known to confer
NNRTI resistance (for example, G190A and G190S) that are seen
much more frequently. Because the selection pressure for NNRTI
resistance is strong, the limitation on the selection of G190E is not
absolute. However, the RTs that carry the G190E mutation have
been reported to carry a number of additional changes that appear,
collectively, to be able to compensate for the presence of the
G190E mutation (Huang et al., 2003). We looked at the Stanford
database to see if we could ﬁnd mutations that were present much
more frequently in the presence of the G190E mutation than in its
absence. Although there were a number of mutations that
appeared frequently (mutations that were present in 433% of
the sequences in the database that carried the G190E mutation),
all of these substitutions were also seen quite frequently in the
absence of the G190E mutation; thus all could be classiﬁed as
polymorphisms, not mutations (Table 2). However, of the 11
polymorphisms that were on the on the list we derived from the
Stanford database, 6 (K122E, T200A, R211K, A272P, T286A, and
E297K) were listed as compensatory mutations in the RT of a
patient derived virus that carried the G190E mutation. This virus
had, relative to WT, a reduced, but signiﬁcant, residual replication
capacity that was much greater than an RT that carried only G190E
(Huang et al., 2003). The data reported by Huang et al, and to a
lesser extent, the data in the Stanford database, are heavily biased
towards the amino terminal two-thirds of the RT coding region,
and there might be additional polymorphisms/mutations that
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would appear on both lists if we had more complete information.
One simple explanation for the prevalence of these mutations/
polymorphisms in the Stanford database is that some or all of
these mutations, and perhaps others that are normally thought of
as polymorphisms, increase the stability of RT, allowing it to carry
mutations that would otherwise make it PR-sensitive. However, if
this is the correct explanation, it would appear that no single
polymorphism is sufﬁcient, and that several changes must colla-
borate to compensate for the effects of a PR-sensitive mutation
like G190E.
Despite the possibility that there are compensatory mutations
that can help to stabilize RT, all of the protease sensitive mutations
that we describe here comprise only a small fraction of the RT in
the Stanford database. More importantly, in almost every case, the
mutations that we showed confer PR-sensitivity also comprise
only a small fraction of the amino acid substitutions at the position
(s) in question, which suggests that these protease sensitive
mutations are selected against in patients. To conﬁrm this idea,
we also looked at the prevalence, in patients, of mutations at sites
where we previously reported amino acid substitutions that can
make RT PR-sensitive. The ratio WT to mutant amino acids is low
at a number of these positions. The ratio is 1 in 100 or less at
positions 78, 256, 264, 274, 279 and just over 1 in 100 at position
310. Moreover, the fraction of the mutations at most of these
positions that are known to make RT PR-sensitive is also small. For
example there are several PR-sensitive mutations that are present
in less than 2% of the viral isolates that have any amino acid
change at the position of interest (V148S, L274T, L279S, and L310S),
and in two more (D256N, L264S) for which the known protease
sensitive mutations comprise between 4% and 5% of the amino
acid changes seen at these positions. These results support the
idea that the protease-sensitive mutations in the RT coding region
are rare in patient samples. There is only one additional case
(R78K), in which a mutation that confers protease-sensitivity in RT
Table 2
Prevalence, in the Stanford database, of the mutations that make RT sensitive to PR. The table lists the number of WT and mutant sequences for the positions of interest in the
Stanford database, and also lists any mutations that are frequently seen in conjunction with the mutation of interest. SSS means small sample size.
Mutation Location of
the
mutation
Number of WT sequences at
that position in the Stanford
database
Total number of mutant
sequences at the position in the
Stanford database
Ratio of mutant to
WT sequences at the
position
Percent of mutations at the
position that are the
speciﬁed change
Other mutations
associated with the
speciﬁed change
(433.3%)
G45L Fingers 100,856 292 0.0029 0.3% SSS
I63S Fingers 101,165 143 0.0014 0.7% SSS
R78K Fingers 101,137 222 0.0022 79.3% V35T (50.6%)
K122E(51.7%)
Q174K (34.7%)
D177E (47.2%)
T200A (43.2%)
R211K (48.3%)
V245Q (36.6%)
A272P (41.8%)
T286A (68.5%)
P294T (33.7%)
G335D (63.5%)
R356K (54.0%)
M357K (40.0%)
G359S (62.0%)
I375V (35.6%)
A400T (44.7%)
T403M (45.7%)
101,137 222 0.0022 79.3% SSS
V111S Palm 100,456 910 0.0091 0.0% NA
V118S Palm/
Fingers
92,569 8796 0.0095 0.0% NA
N136Q Fingers 101,226 163 0.0016 0.6% SSS
V148S Fingers/
Palm
101,193 190 0.0019 0.0% NA
I159S Palm 100,764 605 0.0060 0.0% NA
V35T (39.3%)
K122E (64.4%)
D177E (36.2%) T200A
(40.8%)
R211K (45.4%)
A272P (60.8%)
T286A (40.4%)
E297K (39.4%)
M357T (32.0%)
T386I (37.5%)
A400T (50.0%)
G190E Palm 94,931 6383 0.067 2.4% SSS4400
D256N Thumb 61,831 83 0.0013 4.8% SSS
L264S Thumb 57,263 47 0.0008 4.3% SSS
I274T Thumb 55,320 563 0.010 1.4% SSS
L279S Thumb 55,047 280 0.005 0.4% SSS
L310S Thumb 34,666 402 0.012 1.2% SSS
T473A RNase H 5679 15 0.0027 40% SSS
Q475A RNase H 5687 2 0.0004 0.0% NA
Y501A RNase H 5333 5 0.0094 0.0% NA
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makes up a large fraction of the mutations seen at that position in
patients. As was the case with T473A, although the R78K mutation
represents the majority of the mutations that arise at this position,
RTs carrying the R78K mutation make up a relatively small
percentage (less than 1%) of the total RT sequences in the Stanford
database. As might have been expected, R78K does not have the
strongest protease-sensitive phenotype of the mutants we have
tested. A vector that replicates using BH10 RT and carries the R78K
mutation still has residual titer, and the virions have, based on a
western blot, a substantial amount of intact p66 and P51. In
addition, when the sequences of the RTs that were reported to
carry the R78K mutation were analyzed, there were a number of
positions at which there were secondary mutations; however, as
was the case for the G190E mutation, all of these were poly-
morphisms that are present in the Stanford database at a high
frequency in the absence of the R78K mutation. We considered the
possibility that R78K could be selected for, at least under certain
circumstances; however, this mutation has not been reported to
be associated with resistance to any of the standard RT inhibitors,
nor has it been reported to be in a CTL epitope (Yusim et al., 2002).
In considering the results obtained both in the analysis of the
mutant RTs done in vitro, and in cell culture, it would appear that
there are a large number of amino acid changes that make RT PR
(and temperature) sensitive. Many of these mutations have a
profound negative effect on the titer of the virus at the tempera-
ture at which the virus replicates in patients. Although there
appear to be compensatory mutations (some of which have
previously identiﬁed as polymorphisms) that allow the virus to
carry a mutation in RT (for example, G190E) that would otherwise
confer protease sensitivity in WT RT, it appears that the effects of a
mutation on the stability of RT in virions is an important factor
that helps to determine whether or not a mutation is likely to be
present in RT. A search of the Stanford database supports the
conclusion that this applies to viruses that are replicating in
patients, based on the observation that not only do viral genomes
that carry the identiﬁed PR-sensitive mutations make up only a
small fraction of the total, but, in addition, with a small number of
exceptions, the identiﬁed PR sensitive mutations make up only a
very small portion of the mutations at their respective positions.
Materials and methods
Preparation of the expression plasmids and growth of the E. coli
strains
The E. coli expression systems used to generate the various
forms of the HIV-1 RT have been described (Boyer et al., 1994,
2001). The various mutations were introduced in the RT sequence
in the various constructs using the QuikChange Lightning Multi
Site-Directed Mutagenesis Kit (Agilent Technologies: La Jolla, CA).
The vector that encodes and expresses the p66 subunit of RT and
separately encodes and expresses PR was used to generate p66/
p51 heterodimers. For the E. coli expression experiments, we used
a plasmid that expresses the entire Pol coding region in E. coli
(Dunn et al., 2013). The Pol region was derived from the HIV-1
clone BH10 (Genebank #HIVBH102). The plasmids that encode
both p66 and PR, and the Pol expression plasmids express PR,
which is toxic to the bacteria. These proteins are therefore
expressed in the IPTG-inducible vector pT5m. To express Pol, a
glycine codon located in p6n (nucleotide #1545) 22 codons from
the beginning of the protease coding region was selected as the
start position. PCR ampliﬁcation was used to add a methionine
initiation codon, and the sequence around the ATG was modiﬁed
to create an NcoI site (CC ATG GGT AGA GAC…..). The same PCR
reaction was used to add a HindIII site 3' of the termination codon
at the end of the IN coding region (nucleotide #4454). The PCR
product was digested with NcoI/HindIII and cloned into the
expression vector pT5m. The vectors were transformed into
Rosetta 2(DE3) Competent Cells (EMD Chemicals). E. coli from an
overnight culture were inoculated 1:80 into pre-warmed NZY/amp
(100 mg/ml) media for two hours at 30 oC or 37 oC. The bacteria
that expressed p66 plus PR or Pol were induced with IPTG
(Isopropyl-beta-D-thiogalactopyranoside at 2.5 mM ﬁnal) for two
hours at either 30 oC or 37 oC. Bacteria were collected by centri-
fugation for 5 min at 325g. Media was removed and the pellets
were resuspended in PBS. For Western blot analysis, 4 ml cultures
were used; the OD600 was measured and equal amounts of E. coli
were collected by sedimentation for 5 min at 325g. The super-
natant was removed and the pellet was resuspended by vortexing
and stored at 70 oC.
Gel analysis of the recombinant RTs
Proteins were extracted from E. coli pellets that had been stored
at 70 oC. The pellets were resuspended in 60 ml of 10 mM Tris-Cl,
1 mM EDTA, 25% sucrose, 5 mg/ml lysozyme, pH 8.0 and placed on
ice 15 min. 82 ml of 50 mM Tris-Cl, 6.25 mM EDTA, 0.1% Triton
X-100, 50 mM NaCl, 0.2 mM PMSF, 8U Benzonase (Novagen),
22 mM MgCl2, pH 8.0 were added to the lysed bacterial pellets,
which were placed on ice 15 min. Polymethyl sulfoxide (PMSF)
was dissolved in ethanol at a concentration of 17.4 mg/ml
(100 mM) and added to the buffer 15 min before the buffer was
used. 180 ml of 50 mM Tris-Cl, 6.25 mM EDTA, 0.1% Triton X-100,
950 mM NaCl, pH 8.0, 0.2 mM PMSF were added and the lysates
were sedimented at 16,000g for 1 h at 4 oC. The supernatants were
removed from the pellet and the OD280 of the supernatants were
measured. Equal amounts of supernatants and pellets (based on
the OD of the supernatants) of the bacteria that expressed WT and
the RT mutant proteins were mixed with loading buffer (ﬁnal
concentration of the loading buffer: 1 NuPage LDS sample
buffer, with 50 mM dithiothreitol), aliquoted, and stored at
70 oC. The samples were heated to 95 1C for 5 min. Protein
samples were fractionated on NuPage 4–12% Bis-Tris gels.
Western Blots
Following fractionation on a NuPage 4–12% Bis-Tris gel (Invi-
trogen) the proteins were wet blot transferred onto Hybond-ECL
nitrocellulose (Amersham). Blots were incubated in block solu-
tion (5% dry milk in Tris-buffered saline-Tween) for more than
1 h. Primary antibody was diluted in 0.5% dry milk in Tris-
buffered saline-Tween, and blots were incubated for 4–24 h.
Blots were washed 10 times for 6 min (1 h total). Secondary
antibody was diluted in block solution, and the blots were
incubated for 2–4 h. The blots were washed 5 times for 6 min
(30 min total), and the antibody was detected with either Super-
Signal West Pico or Supersignal West Femto chemiluminescent
substrates (Pierce). The individual mouse anti-RT antibodies have
been described; the anti-RT MAb mix was prepared using equal
amounts of MAbs 19, 21, 42, 48, and 50 (Ferris et al., 1990). The
mouse anti-RT MAbs were diluted 1:500; mouse anti-PR anti-
body (Exbio #10-302-C100) was diluted 1:2000. The rabbit anti-
IN antibody (kindly provided by Duane Grandgenett) was used at
a dilution of 1:10,000. The experiments were repeated several
times, with different extracts, and the data shown in the ﬁgures
are representative.
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Virus production and infection
293T cells were seeded in 100 mm plates at 1.2106 cells per
plate the day prior to transfection. Cell numbers were determined
by counting in a hemocytometer. Cells were co-transfected with
12 μg of the plasmid encoding the one-round vector pNLNgo-
MIVR-E-HSA, or 12 μg of plasmid encoding the RT mutants, and
3 μg of the plasmid pHCMV-g, which expresses VSV-G (obtained
from Jane Burns, University of California at San Diego) using the
calcium phosphate method. The encoded RTs are derived from
NL4–3 which differs by one amino acid from the group M subtype
B-strain BH10 (see text). At 7 h after the calcium phosphate
precipitate was added, the cells were washed 3 times with
phosphate-buffered saline (PBS), and fresh medium was added.
At this point, one set of plates was incubated at 37 oC and the other
at 32 oC for 40 h. The day prior to infection, 60 mm plates were
seeded with 2105 HOS cells, 4 plates were prepared for each of
the mutants. The morning of infection, the viral supernatants were
collected, clariﬁed by sedimentation for 5 min at 1700g, and 4 mls
of the clariﬁed supernatant was added to one of the plates, and
4 mls of 1:5, 1:25, and 1:125 dilutions was added to three other
plates. Samples were set aside for measuring the amount of each
of the viruses by p24 ELISA. After 4 h, the virus was removed and
fresh media added. At 24 h, plates were rinsed with 1 ml of
Versene (Gibco). One ml Versene was added and incubated for
5 min. Cells were harvested with 3 ml of PBS and collected by
sedimentation. Cells were resuspended in 100 μl PBS and incu-
bated on ice for 30 min after the addition of 2 μl PE Rat Anti-
Mouse CD24 Heat Stable Antigen (BD Pharmingen, BD Bios-
ciences). Cells were washed twice with PBS, resuspended in
150 μl PBS, and added to 150 μl 4% paraformaldehyde. The relative
virus titer was determined by counting the number of cells that
express the mouse CD24 Heat Stable Antigen marker (HSA) and
expressing the data relative to p24 ELISA data.
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